GlassScriptPhysician profile
Ross A Lange
NPI 1396778270
$876.87
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $121 · 2021: $215 · 2022: $106 · 2023: $89.63 · 2024: $24.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.61 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $241.90 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $54.51 | 2019-2021 | |
| Glaxosmithkline, LLC. | $41.82 | 2019 | |
| Lilly USA, LLC | $33.97 | 2019 | |
| Amgen INC. | $27.96 | 2019 | |
| Roche Diagnostics Corporation | $24.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.90 | 2019 | |
| Allergan, INC. | $16.58 | 2019 | |
| Astellas Pharma US INC | $15.86 | 2019 | |
| Abbvie INC. | $15.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.23 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.92 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Lange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.